Arena virus monoclonal antibodies and uses

US12358971B2 · kind B2 · utility

Assignees

• The Administrators of the Tulane Educational Fund · US
• The Boad of Regents of the University of Texas System · US
• THE SCRIPPS RESEARCH INSTITUTE · US
• Zalgen Labs, LLC · US

Inventors

• Luis M. Branco · Germantown, US
• Robert F. Garry · New Orleans, US
• James E. Robinson · Genval, BE
• Erica Ollmann Saphire · Solana Beach, US
• Kathryn M. HASTIE · Village of La Jolla, US
• Thomas W. Geisbert · Albany, US

Key dates

• Filing date: Dec 21, 2023
• Grant date: Jul 15, 2025
• Expiry date: Dec 21, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/10011
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.